Advertisement

BMC Infectious Diseases

, 13:O29 | Cite as

Neurocognitive impairment screening in Romanian HCV infected patients

  • Ioana-Catrinel Cercel
  • Șerban Polli
  • Oana Streinu-Cercel
  • Anca Streinu-Cercel
  • Adrian Marinescu
  • Adrian Streinu-Cercel
Open Access
Oral presentation
  • 530 Downloads

Keywords

Public Health Internal Medicine Infectious Disease Cognitive Deficit Usual Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Background

Neurocognitive impairment can occur in HCV infected patients. A series of studies have shown that patients with HCV may experience diminished attention and concentration, or suffer from severe cognitive deficits, such as disorientation and fluctuating consciousness. We performed a study to determine if there are neurocognitive differences or dissimilarities in the quality of life between a control group and a group of HCV infected patients.

Methods

We assessed patients by applying the EQ-5D-5L questionnaire and the Montreal Cognitive Assessment. EQ-5D-3L comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Montreal Cognitive Assessment indicates if patients have neurocognitive impairment. All subjects were evaluated with these questionnaires during an appointment with the clinical psychologist.

Results

We assessed 11 HCV infected patients and 11 controls. The HCV group had ages between 25-58 with a median of 40±12 (2 retired, 1 doctor, 1 economist, 2 engineers, 1 architect, 1 editor, 1 clerk, 1 financial analyst) and the control group had ages between 26-38, median 30±4 (7 doctors, 3 nurses and 1 secretary). EQ-5D-5L scores were 85±10 percent (min: 65, max: 95) in the HCV group and 95±7 percent (min: 85, max: 100) in the control group. The median MOCA scores were 28±4 (min: 19, max: 31) in the HCV group and 30±3 (min: 22, max: 31) in the control group.

Conclusion

At a first look, we identified apparent neurocognitive differences between the two groups but the number of subjects was too low to offer a statistical significance. We intend to evaluate larger groups of patients, and reapply the tests periodically to determine if there are longitudinal changes in the neurocognitive status.

Copyright information

© Cercel et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Authors and Affiliations

  • Ioana-Catrinel Cercel
    • 1
  • Șerban Polli
    • 1
  • Oana Streinu-Cercel
    • 1
    • 2
  • Anca Streinu-Cercel
    • 1
    • 2
  • Adrian Marinescu
    • 1
  • Adrian Streinu-Cercel
    • 1
    • 2
  1. 1.National Institute for Infectious Diseases “Prof. Dr. Matei Balş”BucharestRomania
  2. 2.Carol Davila University of Medicine and PharmacyBucharestRomania

Personalised recommendations